Search research articles
Contact Us
Filters
Showing results (171-180 of 180) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 180 results.
Urology
|
April 20, 2021
Preventing Prostate Biopsy Complications: to Augment or to Swab?
Lydia Glick, Sage A Vincent, Danielle Squadron, et al.
Urology
|
September 7, 2021
EDITORIAL COMMENT
Lydia Glick, Sage A Vincent, Danielle Squadron, et al.
Urology
|
July 3, 2023
Longitudinal Changes in the Operative Experience for Junior Urology Residents
Ezra J Margolin, Daniel Schoenfeld, Caleb H Miles, et al.
Cancer Medicine
|
May 24, 2019
Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer
Benjamin W Fischer-Valuck, Jeff M Michalski, Nandita Mitra, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 12, 2016
Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy
Brian C Baumann, Walter R Bosch, Amit Bahl, et al.
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
European Urology
|
December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
Anirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
John L Gore, Erika M Wolff, Michael G Nash, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 180) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 180 results.
Urology
|
April 20, 2021
Preventing Prostate Biopsy Complications: to Augment or to Swab?
Lydia Glick, Sage A Vincent, Danielle Squadron, et al.
Urology
|
September 7, 2021
EDITORIAL COMMENT
Lydia Glick, Sage A Vincent, Danielle Squadron, et al.
Urology
|
July 3, 2023
Longitudinal Changes in the Operative Experience for Junior Urology Residents
Ezra J Margolin, Daniel Schoenfeld, Caleb H Miles, et al.
Cancer Medicine
|
May 24, 2019
Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer
Benjamin W Fischer-Valuck, Jeff M Michalski, Nandita Mitra, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 12, 2016
Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy
Brian C Baumann, Walter R Bosch, Amit Bahl, et al.
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
European Urology
|
December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
Anirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
John L Gore, Erika M Wolff, Michael G Nash, et al.
Page
of 18